Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.
- THE TICK ACT: AN URGENT PUBLIC HEALTH RESPONSE TO TICK-BORNE DISEASES [Senate Hearing 116-543] [From the U.S. Government Publishing Office] S. Hrg. 116-543 THE TICK ACT: AN URGENT PUBLIC HEALTH RESPONSE TO TICK-BORNE DISEASES ======================================================================= HEARING BEFORE THE SPECIAL COMMITTEE ON AGING UNITED STATES SENATE ONE HUNDRED SIXTEENTH CONGRESS FIRST SESSION __________ ORONO, MAINE __________ SEPTEMBER 5, 2019 __________ Serial No. 116-11 Printed for the use of the Special Committee on Aging [GRAPHIC NOT AVAILABLE IN TIFF FORMAT] Available via the World Wide Web: http://www.govinfo.gov __________ U.S. GOVERNMENT PUBLISHING OFFICE 47-293 PDF WASHINGTON : 2022 ----------------------------------------------------------------------------------- SPECIAL COMMITTEE ON AGING SUSAN M. COLLINS, Maine, Chairman TIM SCOTT, South Carolina ROBERT P. CASEY, JR., Pennsylvania RICHARD BURR, North Carolina KIRSTEN E. GILLIBRAND, New York MARTHA McSALLY, Arizona RICHARD BLUMENTHAL, Connecticut MARCO RUBIO, Florida ELIZABETH WARREN, Massachusetts JOSH HAWLEY, Missouri DOUG JONES, Alabama MIKE BRAUN, Indiana KYRSTEN SINEMA, Arizona RICK SCOTT, Florida JACKY ROSEN, Nevada ---------- Sarah Khasawinah, Majority Acting Staff Director Kathryn Mevis, Minority Staff Director C O N T E N T S ---------- Page Opening Statement of Senator Susan M. Collins, Chairman.......... 1 PANEL OF WITNESSES Lyle Petersen, M.D., MPH, Director, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.............................................. 4 James Dill, Ph.D., Pest Management Specialist and Diagnostic and Research Lab Coordinator, University of Maine Cooperative Extension, Orono, Maine........................................ 5 Sean McCloy, M.D., MPH, MA, Medical Director, Integrative Health Center of Maine, Cumberland Foreside, Maine.................... 7 Paula Jackson Jones, President and Co-Founder, Midcoast Lyme Disease Support and Education, Nobleboro, Maine................ 9 Christopher Philbrook, Individual Affected by Lyme Disease, Cumberland, Maine.............................................. 11 APPENDIX Prepared Witness Statements Lyle Petersen, M.D., MPH, Director, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.............................................. 27 James Dill, Ph.D., Pest Management Specialist and Diagnostic and Research Lab Coordinator, University of Maine Cooperative Extension, Orono, Maine........................................ 34 Sean McCloy, M.D., MPH, MA, Medical Director, Integrative Health Center of Maine, Cumberland Foreside, Maine.................... 36 Paula Jackson Jones, President and Co-Founder, Midcoast Lyme Disease Support and Education, Nobleboro, Maine................ 38 Christopher Philbrook, Individual Affected by Lyme Disease, Cumberland, Maine.............................................. 41 Statements for the Record Holly Noonan, Testimony.......................................... 45 Dr. Kristen Honey, Testimony..................................... 47 Joel Beaule, Testimony........................................... 52 Michaela Cisowski, Testimony..................................... 53 Maine Medical Center Research Institute Letter................... 56 Paula Doucette, Testimony........................................ 58 Tracey Allen, Testimony.......................................... 59 THE TICK ACT: AN URGENT PUBLIC HEALTH RESPONSE TO TICK-BORNE DISEASES ---------- THURSDAY, SEPTEMBER 5, 2019 U.S. Senate, Special Committee on Aging, Washington, DC. The Committee met, pursuant to notice, at 10:06 a.m., at the University of Maine Cooperative Extension Diagnostic and Research Laboratory, Orono, Maine, Hon. Susan M. Collins (Chairman of the Committee) presiding. Present: Senator Collins. OPENING STATEMENT OF SENATOR SUSAN M. COLLINS, CHAIRMAN The Chairman. Good morning, everyone. This official hearing of the Senate Special Committee on Aging will come to order. First, let me welcome everyone who is here today. Lyme disease and other tick-borne diseases have soared in Maine and across the country during the past 15 years. Many of you here today have had firsthand experiences with the devastating consequences of tick-borne diseases. I would like to take just a moment to recognize Susie Whittington, whose mother, Lyn Snow, a well-known artist who captured Maine so beautifully, tragically died in 2013 from the deadliest tick- borne disease known as ``Powassan.'' Thank you so much, Susie, for being here with us today. My thanks also to the University of Maine Cooperative Extension's Tick Lab for hosting this hearing. I just toured the lab, and I was so impressed with the extraordinary research and work that is going on here. I saw firsthand how its outstanding work is advancing our understanding of the diseases that ticks carry and how the employees of the lab are working every day to protect Mainers. They also do a host of other important work in this lab, and it was wonderful to learn more about it, so thank you, Jim Dill, for arranging for the tour and for all you did to welcome us. In Maine last year, there were approximately 1,400 new cases of Lyme disease, nearly double the number of cases as 2010, as we can see from this chart. Listen to this fact: The incidence of Lyme disease in Maine is the highest in the country, at 107 cases per 100,000 Mainers, which is 10 times higher than the national average. I was talking with President Joan Ferrini-Mundy here today and talking about the work that the lab is doing and the university is doing and how incredibly important it is, and it includes this tick removal kit, which the lab will make available to anyone who wants one and which our wardens and other State employees who are working outside, like Inland Fisheries and Wildlife, can use. Other tick-borne diseases are also on the rise. For example, anaplasmosis, related to rickets, has increased by more than five-fold. While ticks do not discriminate and the diseases they carry affect Americans of all ages, tick-borne diseases disproportionately affect people over the age of 65, and that is why, as Chairman of the Aging Committee, I thought it would be appropriate for us to hold this hearing. From children to seniors, far too many Americans with Lyme disease experience a complex diagnostic odyssey that takes months or even years. One of my nieces, Catherine Collins, contracted Lyme disease and had a very difficult time getting an accurate diagnosis. She went on to get Lyme disease two additional times, but at least in those cases she knew what to look for. Regrettably, her story is not at all unusual, as we will learn from our witnesses. In addition to the physical and emotional toll that Lyme disease can impose, it is also expensive. Medical costs of Lyme disease are estimated at $1.3 billion per year. When accounting for indirect medical costs, including the loss of work, the annual costs balloon to $75 billion per year. A correct and early diagnosis can reduce costs and improve the prognosis, but we have a long way to go. When HIV became a public health crisis, a gold standard for identification and treatment was developed within 10 years. Lyme disease was identified more than 40 years ago, yet there still is no gold standard for treatment. Existing prevention, education, and diagnostic efforts are helpful but remain fragmented. It is time for us to unite in the fight against ticks. Earlier this year, I introduced the bipartisan bill with Minnesota Senator Tina Smith and my Maine colleague, Senator Angus King. It is called ``The TICK Act.'' ``TICK'' in the name of our bill stands for ``Ticks: Identify, Control, and Knockout.'' Through a uniform and unified approach, this legislation would arm local communities and States with the resources they need for prevention, early detection, and treatment of tick-borne diseases. The TICK Act would apply a three-pronged approach to tackle Lyme and other tick-and vector-borne diseases. First, it would establish an office to develop a national strategy to prevent tick-borne diseases. Second, the bill would reauthorize the Centers for Disease Control Regional Centers of Excellence in Vector-Borne Diseases that have led the scientific response to fighting ticks. Finally, the bill would establish grants to support State health departments' efforts to improve data collection and analysis, early detection and diagnosis, treatment, and public awareness, and that indeed is one of the purposes of our hearing today, to increase public awareness. We are very fortunate to have with us a truly extraordinary group of witnesses, including national, State, and local experts. I also am very pleased that we have two individuals who are going to share with us their personal experiences with Lyme disease. These individuals will give us their insights on what it has been like to have Lyme disease and will share their journey and their advocacy efforts with us. They are Paula Jackson Jones and Christopher Philbrook, and I will introduce them in more detail in just one moment. We will now turn to our witnesses. First, I am pleased to welcome the Director of the Division on Vector-Borne Diseases at the Centers for Disease Control and Prevention, Dr. Lyle Petersen. A leading international authority on tick-borne diseases and on vector-borne diseases more generally, Dr. Petersen has worked through epidemics in the past from HIV to Zika. Today he is leading the fight against Lyme. Dr. Petersen, we are really delighted that you have traveled so far to be with us today, and I want to note his personal effort to rearrange his schedule because his daughter is getting married this weekend. He really has made an extraordinary effort to be with us. Next, we will hear from Dr. James Dill, who is also our gracious host here at the University of Maine Cooperative Extension Diagnostic and Research Lab. Dr. Dill serves as the lab coordinator as well as the pest management specialist. His leadership on tick-borne diseases is well known in Maine, both as a scientist and as a policymaker, since he serves in the State Senate. Next, we will hear from Dr. Sean McCloy, the medical director of the Integrative Health Center of Maine, in Cumberland Foreside. Dr. McCloy brings a background of public health and a wealth of knowledge in providing care to patients with tick-borne diseases. I am very pleased that Paula Jackson Jones, an extraordinary advocate who survived Lyme disease and founded a nonprofit organization, the Midcoast Lyme Disease Support and Education Association, and she will be testifying today. Her work has been recognized in Maine and nationally. The Union Fair recognized her organization with an award last month, and she has also been honored to be chosen as a Point of Light, a national recognition for her service for others. You may remember that that organization was first started by President George Bush. Finally, we will hear from a personal friend and former staffer of mine, Christopher Philbrook, who will share his personal struggle with Lyme disease. I have known Chris for years and how well I remember when he was working with me and trying to figure out this bizarre set of symptoms that he had. He will describe how this disease has affected his life, and I am very thankful for his willingness to be public with his story. I want to thank all of you for joining us today. We look forward to hearing your testimony, and Dr. Petersen, we will start with you. Before we do that, I want to run one brief advertisement here for the lab. I want you all to pick up the tick removal kit that you will find on your chair, and this will be very helpful to you if you find, after walking in the woods or gardening or hunting, this being outside, that you have picked up a tick, and it will tell you what to do, and the University of Maine does an extraordinary job in identifying ticks and also telling you whether or not they carry a pathogen. Dr. Petersen, thank you for being here. Please proceed. STATEMENT OF LYLE PETERSEN, M.D., MPH, DIRECTOR, DIVISION OF VECTOR-BORNE DISEASES, NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES, CENTERS FOR DISEASE CONTROL AND PREVENTION, FORT COLLINS, COLORADO Dr. Petersen. Good morning, Chairwoman Collins. I am Dr. Lyle Petersen, Director of CDC's Division of Vector-Borne Diseases. Thank you for the opportunity to testify before you today on our efforts to protect the U.S. from the growing threat of vector-borne diseases, and tick-borne diseases in particular. We appreciate your continued commitment and support in this area. I lead our agency's efforts to research, prevent, and control viruses and bacteria spread by mosquito, tick, and flea vectors. These vectors transmit over 100 pathogens known to infect people, including West Nile, Zika, Lyme disease, and plague. We recently examined trends in vector-borne diseases and found that the reported cases in the U.S. tripled from 2004 to 2016. During this same period, tick-borne disease cases more than doubled, and the U.S. experienced several mosquito-borne outbreaks, including Zika. In 2017, reported cases again increased for all nationally notifiable tick-borne diseases. We are particularly concerned about vector-borne diseases in Maine. Reported cases continue to rise steadily over time, with more than 98 percent of them being tick-borne. On a population basis, as Senator Collins noted, Maine had the highest incidence of Lyme disease in the Nation, with more than 1,800 cases of Lyme disease reported in just 1 year. Maine also had the second highest incidence of anaplasmosis, second only to Vermont. These statistics are of great concern to us, and we are working closely with the Maine CDC and academic institutions to address this growing threat. Why are we seeing more diseases than ever before? There are at least three major factors at play. First, we know more about vector-borne disease pathogens than ever before. In the last 13 years, 9 new vector-borne pathogens were identified in the U.S., including Zika and seven new tick-borne pathogens. Second, travel and trade are moving more pathogens and vectors around the world. Zika virus was an example of the impact that travel can have on the spread of disease. The U.S. had more than 5,000 reported cases in 2016 of which most were in travelers returning from infected areas. Third, existing vectors continue to expand across the U.S. For example, the ticks that spread Lyme disease and other tick- borne diseases are now found in 1,500 U.S. counties covering 43 States. This marks a 45-percent increase in the number of counties that have recorded these ticks since 1998. We now have another tick that could pose a threat to the public's health. The Asian longhorned tick was first discovered in New Jersey in 2017 and has now been identified in 11 additional States. This tick causes massive infestations and transmits several vector-borne diseases throughout the world. To date, this tick has not been found in Maine; however, models suggest that Maine has a suitable habitat for this tick. State tick surveillance activities, funded by CDC, should allow for early detection if this tick arrives in the State. What are we doing to address all of these threats? We know that vector-borne disease can be devastating to families in Maine and across the Nation. CDC is committed to addressing Lyme and other tick-borne diseases. We are improving diagnostics so that doctors can best support patient outcomes. We disseminate the best scientific information to health care professionals and the public and work with State and local partners to ensure that Lyme disease prevention and information are readily accessible. We are grateful to Congress for their support in the years following Zika, which has enabled us to increase support for vector-borne disease prevention and control across 64 U.S. jurisdictions while providing enhanced support to nine States and one U.S. city at high risk for disease. We know that there are still unmet needs. For example, many State health departments in the Northeastern U.S. like the Maine CDC have expressed concerns that they are hard-pressed to address both Lyme disease and anaplasmosis, especially because the incidence of anaplasmosis has more than doubled in the last 4 years. CDC is committed to reversing the upward trends in vector- borne disease. However, it is clear that this will not be easy. There are no proven community prevention methods for the most common tick-borne diseases as well as many mosquito-borne diseases. Although we can control certain mosquito-borne diseases, current national, State, and local capacity is limited. Finally, there are no human vaccines for any vector- borne diseases found in the U.S. We are committed to making strategic investments in promising new prevention strategies, including informing and supporting vaccine development and implementation, as vaccines become available. Thank you again for the opportunity to appear before you today and for your support of our fight to protect the U.S. and its territories from the growing threat of vector-borne diseases. I am happy to answer any questions that you may have. The Chairman. Thank you, Dr. Petersen. Dr. Dill. STATEMENT OF JAMES DILL, Ph.D., PEST MANAGEMENT SPECIALIST, AND DIAGNOSTIC AND RESEARCH LAB COORDINATOR, UNIVERSITY OF MAINE COOPERATIVE EXTENSION, ORONO, MAINE Dr. Dill. Well, good morning, everyone, and welcome to the University of Maine, and thank you especially to Senator Collins for the opportunity to speak before the Special Committee on Aging in regard to the increasing challenges associated with combating tick-borne disease here in Maine. As the pest management specialist for University of Maine Cooperative Extension and a State Senator in the Maine Legislature, I have had the unique opportunity to experience these challenges from both the political and scientific perspectives, but today I will speak from my university perspective. Tick populations have undergone extensive range expansion over the past 50 years, particularly here in the Northeast. Multiple factors, including reforestation, changes in climate, and increased abundance of wildlife hosts such as rodents and white-tailed deer, have contributed to this surge. Maine is a heavily forested State with a largely rural population that spans four degrees of latitude and maintains a robust wildlife population. As such, we have witnessed a dramatic increase in the number of ticks, their geographic distribution, and the subsequent incidence of tick-borne disease. This increase in tick-borne diseases has rapidly become a significant public health issue in Maine and throughout much of the United States. The incidence and distribution of these pathogens continues to increase, often resulting in severe health issues for those affected. In addition to the public health threats associated with tick-borne disease, societal and economic costs have also had economic impacts. Of the roughly 13 tick-borne diseases identified in the United States, 5 have been found in Maine, including Lyme disease, anaplasmosis, babesiosis, Borrelia miyamotoi disease, and Powassan encephalitis. The primary vector of these pathogens, the deer tick or black-legged tick, has greatly increased in both population size and geographic range within the State. Furthermore, Maine faces significant threats related to invasive tick species including the lone star tick and, as just mentioned, the Asian longhorned tick, both of which can have serious impacts on the health of humans, wildlife, and domestic animals. Combating these threats is an immense challenge that relies heavily on an integrated approach that includes investment in new medical treatments, diagnostics, and vaccines, as well as research into monitoring tick populations, reducing tick and host habitat, managing ticks and their wildlife hosts, and widespread educational outreach. Maine has been fortunate to have a relatively long history of research and outreach on tick-related issues thanks to a collaborative network of private and public institutions. The Maine Medical Center Research Institute has been conducting research on ticks and vector-borne disease since the late 1980's and has emerged as a leader in the field. Maine CDC has taken a proactive role, combining epidemiology with widespread public outreach efforts to help minimize the spread of tick- borne diseases. Many States have stopped counting cases of Lyme disease due to the high burden placed on State health departments and have begun instead estimating their cases. These estimates can vary in their accuracy, thus affecting the regional and national rates of disease. Maine CDC is still counting individual cases, but as the burden continues to increase and funding remains limited, a transition to an estimation system also might be likely. At the University of Maine, significant research is underway both in the School of Biology and Cooperative Extension. A primary goal of UMaine Extension is to explore ways to minimize the occurrence and spread of ticks and tick- borne disease in Maine. Understanding the shifts in tick population size and geographic range is critical in evaluating risk and targeting management strategies. UMaine Extension currently monitors tick populations through a public tick identification program and tick-borne disease screening program. Through these programs, Maine residents can send tick samples to the lab for identification and to test whether the ticks are carrying the pathogens that cause Lyme disease, anaplasmosis, and babesiosis. Additional pathogens are scheduled to be added to the testing program in 2020. A small- scale active surveillance program is also ongoing, in which ticks are actively monitored through field survey methods. Additional active monitoring of small mammal hosts is also ongoing. The information generated from these programs will allow us to track the distribution of ticks and tick-borne disease in Maine and to identify priority areas for targeting prevention and management strategies. The University of Maine School of Biology and Ecology is currently investigating multiple avenues related to the ecology of tick-borne disease, including the environmental conditions that enhance disease transmission, the impacts of climate change and human land-use patterns on ticks, as well as the risks related to tick-borne disease in Acadia National Park and its potential effects on the tourism industry. The public demands and political will to fight Lyme disease and other tick-borne diseases are strong in Maine; however, as with many rural States, the funding to wage such a battle is limited. Nonetheless, the people of Maine prioritized this battle in 2014 when voters approved a bond referendum to create the new University of Maine Cooperative Extension Diagnostic and Research Laboratory. Following several years of intense planning and construction, the new lab opened in June 2018. This high- containment facility brings together research on animals, plants, and arthropods within one biosecure setting and has greatly enhanced the university's diagnostic capabilities. The construction of this facility has also broadened the university's collaborative efforts, facilitating collaborations between UMaine, Maine CDC, and the Maine Medical Center. Through the work being done at UMaine Extension, the University of Maine School of Biology and Ecology, Maine Medical Center, and the Maine CDC, the State has a solid infrastructure in which to tackle the issues surrounding tick- borne disease. Historically, however, funding for tick-related research and particularly outreach and education has been a relatively low priority. The TICK Act will inject a much-needed investment into research and education and allow us to leverage existing infrastructure to fund novel approaches to monitoring and managing ticks and tick-borne disease. Thank you again, Senator Collins, for the opportunity to speak today, and I welcome any questions. The Chairman. Thank you very much. Dr. McCloy. STATEMENT OF SEAN MCCLOY, M.D., MPH, MA, MEDICAL DIRECTOR, INTEGRATIVE HEALTH CENTER OF MAINE, CUMBERLAND FORESIDE, MAINE Dr. McCloy. Thank you, Senator Collins, as well as to the esteemed members of this panel, and especially to Paula Jackson Jones for setting the temperature controls and getting us all ready for winter. I am honored to speak about my experiences and my frustrations as a physician treating patients with tick-borne disease. No other illness has been as intellectually challenging to properly diagnosis and manage as Lyme. The more I learn about this disease, the more questions I have, and the more I realize we have just scratched the surface of how complex the answers are. Hopefully your work on the TICK Act will move the research forward and provide more hope and more help to Mainers and to the worldwide public health. As a young resident at Maine Medical Center, I felt I was well trained in the classic signs and symptoms of Lyme Disease. We were taught to look for the bull's-eye rash, the flu symptoms outside of flu season, the joint pain. Like my colleagues, I treated these acute cases with a short course of antibiotics. However, I began to see more and more patients who did not fit the typical scenario. They never remembered a tick bite; they never had a rash. Their blood testing was negative for tick-borne illness, but they grew sicker and sicker despite seeing multiple specialists. I had to become a detective doctor to figure out how to help these people. I needed new tools for my tool box. I began attending conferences run by the International Lyme and Associated Diseases Society, or ILADS, and learned that there was more to the story than the basic model I was taught in medical school. I learned that there were differing opinions and conflicting guidelines between the Infectious Diseases Society of America, or IDSA, and ILADS. In short, IDSA states that Lyme disease is easily diagnosed with standard two-step blood testing and easily treated with a short course of antibiotics. If patients' symptoms persist, it is because of the damage already done and not because of a lingering infection. ILADS' view is just the opposite: the standard testing may not be accurate because of how Lyme can fool the immune system, and a short course of antibiotics may not be enough to eradicate all organisms in a person's body. ILADS feels that chronically ill individuals need a more comprehensive and long-term therapeutic regimen to treat their real disease, and not just be dismissed as suffering from ``the aches and pains of daily living.'' Here we had two groups of very smart doctors, both wanting to help their patients, at loggerheads over how to diagnose and treat Lyme disease. This conflict left me and my patients in the middle searching for solutions. Now, I have got a Master's in Public Health and a Master's in Medical Sciences, so I love research. I dove into the literature from the standpoint of an open-minded skeptic. I read both sets of guidelines. I read the peer-reviewed journal articles supporting both sets of guidelines. I looked into who the authors were and who was paying for their research. In the end, I tried both sets of guidelines on my real-life patients to observe which approach works best. I found there was room for both the IDSA and ILADS solutions depending on the situation. The IDSA approach works well for acute, classic Lyme disease. If a person has a strong, healthy, robust immune system at baseline, then the testing should begin to turn positive after 2 to 3 weeks of infection. Fortunately, this infection is usually very easy to treat with a short course of antibiotics if you catch it early. Unfortunately, if you do not catch it early, this smart little spirochete begins to go through its own life cycle. It changes its shape and hides from the immune system, causing inaccurate, false negative blood testing. It creates a physical barrier called a ``biofilm'' that protects it from antimicrobials and from your own white blood cells. We are discovering what are called ``persister cells'' that are resistant to antibiotic therapy. They can remain dormant in a human body for months or years before they wake up again. In the unfortunate individuals who become chronically ill, multiple systems are affected. There is a complex interplay of genetic factors, inflammation and immune dysregulation, hormonal imbalance, neuroendocrine disruption and neuroinflammation leading to cognitive deficits and psychological illness, gastrointestinal dysfunction causing nutritional insufficiencies, which create metabolic imbalance and poor mitochondrial function, leading to the chronic fatigue that many describe, so lots of big words there. As I learned, a few weeks of antibiotics are not enough to heal these complex cases. The ILADS approach works better for these types of patients. It is an individualized, head-to-toe, integrative method of figuring out what is broken, what are the root causes of the illness, and how to help that person heal from the inside out. It is certainly not a perfect approach. Sometimes it requires long-term antibiotics that have their own risk of side effects. It is complicated and it takes a lot of the practitioner's time to do the detective work. It also takes a lot of the patient's time and energy and health care dollars to walk that road to recovery. These people need a lot of support to get them through the bad days. Eventually, they celebrate more and more good days and move forward to remission. To summarize, I have learned that there is no perfect set of guidelines, no one-size-fits-all algorithm that works for every case in the real world. The testing is imperfect. The medications do not always work. Some people get better right away, and some people develop problems that linger for years. The classic presentation of Lyme disease that physicians learn about in medical textbooks does not always apply because the little bug forgot to read the textbook. We need more answers, Senator Collins. How can we prevent the illness in the first place? How can we improve the accuracy of the testing? How can we tell which treatments work best, and how do we know when to discontinue a regimen? Your excellent work with the TICK Act will hopefully help provide more answers to the doctors and patients out there dealing with tick-borne disease. Thank you very much and be well. The Chairman. Thank you very much, Doctor. Ms. Jackson Jones. STATEMENT OF PAULA JACKSON JONES, PRESIDENT AND CO-FOUNDER, MIDCOAST LYME DISEASE SUPPORT AND EDUCATION, NOBLEBORO, MAINE Ms. Jackson Jones. Chairman Collins, thank you for holding this hearing and for inviting me to testify today. My name is Paula Jackson Jones, and I am here to share with you my personal story and my life's work. This has been a 10-year crusade for me, with the first 5 years fighting for my life and the latter fighting on behalf of others. I was bitten by a tick in October 2009 while outside doing fall cleanup with my husband. At the end of the day, I discovered a tick embedded in my side. We removed it, flushed it, and did not gave it another thought, not even when I became symptomatic 10 days later. For the next 2 years, I was misdiagnosed by 23 doctors and specialists with everything from panic attacks to respiratory infections, chronic fatigue to fibromyalgia. When my neurological symptoms intensified, a scan revealed lesions on my brain, and I was diagnosed with MS. When my symptoms became even more severe and I was not responding to treatment, I was reevaluated, and my diagnosis was changed to Parkinson's. I was 36 years old. When I began to have trouble swallowing and the use of my arms and legs was a daily challenge, my medical providers wanted me tested for ALS. I knew that was a death sentence for me, and it was at this point I knew that I needed to fight and advocate for myself. Thanks to a family member who kept pressing me to be checked for Lyme disease, even though I had four negative tests, I demanded to see a provider who knew about Lyme. My primary doctor refused to give me a referral because that was not what they thought I had. However, the intern gave me a scrap of paper with the name of someone he knew who saw Lyme patients, and in April 2011, after clinical examination, additional blood work, and tests, I was officially diagnosed with late-stage neurological Lyme complicated by Babesia, Bartonella, Rocky Mountain spotted fever, and ehrlichiosis. I was CDC-positive for all these tick-borne diseases. That Maine doctor, the 24th medical provider that I met with, not only saved my life but gave my life back to me. When a cancer doctor thinks outside the box and heals their patient, they are deemed a hero. When a Lyme provider does it, they are brought up under medical scrutiny and disciplined beyond belief. My treatment was not conventional or mainstream, but it was effective. It was tailored to my infections and to how I was responding every step of the way. Thankfully, my medical provider had a vast amount of resources to turn to when treatment options failed, which they did, and I am so grateful for my health today. In April 2014, after going into remission, I wanted to make a difference by raising awareness about the risk of tick-borne disease, educating people on how to protect themselves, but more importantly, I wanted to make their search for resources easier, accessible, and affordable, and so I co-founded Midcoast Lyme Disease Support and Education to connect patients and their families with the services that they need to journey back toward health and wellness. We are a nonprofit 501(c)(3) organization that travels statewide, raising awareness, fostering education, advocating for change, and providing support to those in Maine afflicted by tick-borne disease by linking them with medical providers, educational programs, and financial assistance. We are also the Maine partner of the national Lyme Disease Association, members of Maine's CDC Vector-borne Work Group, and active in Maine's Lyme legislation movement. In 2018, I served as the co-chair to the Federal Health and Human Services Tick-borne Disease Working Group's Access to Care Services and Patient Support Subcommittee. Our task was to identify gaps and barriers that patients faced in accessing proper diagnosis and treatment. That information went into a report and was presented to Congress. I was very honored to have been selected for that role. Tick-borne disease is not a cookie-cutter disease, which explains why the cookie-cutter approach has failed time and time again. Today each of us on this panel has highlighted the increasing incidence of tick-borne disease infections and even viruses which could cause serious illness and death. Excuse me. The actual numbers are likely much higher since experts agree that the public health burden of tick-borne disease is considerably underreported. That is why it is so imperative that we adopt an all-hands-on-deck public health approach. We need to build a robust understanding of pathogenesis, design improved diagnostics, and develop preventative and effective vaccines. We need to fix faulty tests and increase physician education. Enacting the TICK Act that Senator Collins introduced will provide a lifeline not only to patients but to medical providers. With funding available for research and education, we can get medical providers on the same page, not only with improved diagnostic tools but better, more effective treatment options for their patients. With the TICK Act, we can stem the growing threat of tick-borne disease. Thank you again for this opportunity, and I look forward to your questions. The Chairman. Thank you so much for your moving testimony and sharing your personal odyssey with us and all the good work you have done for others as well. Ms. Jackson Jones. Thank you. Mr. Philbrook. STATEMENT OF CHRISTOPHER PHILBROOK, INDIVIDUAL AFFECTED BY LYME DISEASE, CUMBERLAND, MAINE Mr. Philbrook. Thank you, Senator. It is a small thing, but I did not realize how important smiling was to my mental health until I could not do it anymore. On a Saturday afternoon in 2007, I took a trip to Hogback Mountain in Virginia. Shortly after that trip, I woke up incapacitated. I could barely move a muscle. I thought it might be the flu, so I stayed in bed and did not think much of it. I have always been healthy and quick to recover, so when my condition did not improve in a few days, I flew back to the great State of Maine to see my doctor. One problem with Lyme disease is that the symptoms mimic so many other things, as I would soon discover and as Paula just mentioned in her testimony. When I got home, my seventh cranial nerve, which runs down the left side of my face and you can still see, went into a State of trauma. In addition to flu-like symptoms, I now also had Bell's palsy. I also could not eat or sleep for days and was in a State of pain so debilitating that I went to the emergency room and received a CAT scan. The scan showed nothing abnormal, so the doctor suggested I see a neurologist. I also scheduled a dentist appointment to see if something was wrong with my teeth because they hurt badly. The dentist took one look at me and said, ``Bell's palsy can be the result of Lyme disease. Do you have a tick bite or a bull's-eye rash?'' I did not. I mentioned this to my neurologist, and he tested me for Lyme. The test came back negative--a false negative, which is something Dr. McCloy just said in his testimony. Shortly after that, the right side of my face went into a State of paralysis. I now had Bell's palsy on both sides of my face, and my mouth was almost completely wired shut, so the neurologist recommended an MRI. The MRI showed what looked like a tumor either growing or blocking my cavernous sinus, which is a nerve that runs from the brain to the face. We started talking about surgery and radiation. Now I am starting to worry. Next, the neurologist recommended a spinal tap. If you have never had a spinal tap, consider yourself very lucky. It is awful. When the neurologist also ordered a second MRI, this time injecting a blue dye into my body so the tumor would show up in greater detail, he also ordered a chest X-ray because I was having trouble breathing. The spinal tap showed Lyme in my spinal fluid, and the blue dye showed that the disease had attacked the nerves in my brain, causing extreme inflammation, but the good news? I did not have a tumor. I did, however, need a PICC line immediately installed. For 4 weeks, the line delivered a strong dose of antibiotics from my bicep to my heart. I was working on Senator Collins' staff at the time. She watched my pain and suffering firsthand. I still have daily notes from her checking in on me. One said, ``You gave us quite a scare.'' It was scary, and it remains scary today knowing that even in my back yard there are ticks. With its proposed public- private partnerships, including pest control, the TICK Act aims to alleviate this threat--a prospect that would relieve a lot of anxiety for anybody who has gone through this. I was lucky my dentist spoke up, that I had a spinal tap-- not a normal Lyme testing protocol--and that my Lyme disease was treated quickly, within the first month and a half. I am happy to say that after my antibiotic treatment, I was cleared of the disease, although the residual effects remain--mainly sleep disturbances and facial paralysis, which you might not notice in the audience, but I am quite certain that the cameras will pick it up, because I have seen it. Others are not so lucky. When Lyme is not diagnosed quickly, co-infections can develop, and the disease can become much more difficult to treat. This happens far too often, which is why the TICK Act's directive for improved diagnostic testing is so important to me. For my ongoing symptoms, the most effective relief has come from food. After 8 years without improvement and having been told the only solution to improve my facial paralysis was plastic surgery, I started on a ketogenic diet and intermittent fasting--something author Tim Ferriss said was the only thing that knocked out his Lyme disease. Within 7 days, I felt movement in my face that I had not felt in years. Because ketosis--nutritional ketosis, which I was trying to achieve--is unrealistic for me to maintain over the long term, I have fallen back on Tom Brady's eating and training regimen, the TB12 method. I figure if it is good enough for him, it is definitely good enough for me. While this approach may not work for everyone, it did work for me. The problem is my story does not scale. I heard this approach by chance on a podcast. Conversely, the TICK Act would create a data base where the treatment approaches and outcomes could be shared immediately in the context where it matters most: in the doctor's office. Thank you, Senator Collins, for this opportunity and for your work on this public health threat. I hope the TICK Act, when enacted, gives people currently suffering with Lyme disease validation and hope that they can and will get better. Thank you. The Chairman. Thank you so much, Chris. I so remember when you got the results that suggested you had the tumor and how worried we were, and then when it turned out that it was not a tumor, we were still so worried because of the symptoms and pain you were experiencing, and I want to thank you for sharing your story with us today as well. Dr. Dill, I would like to start my questioning with you. You told us how UMaine Cooperative Extension accepts tick submissions to identify the different types of ticks and whether or not they are carrying a pathogen. Could you give us some idea, since April 1st when you first got the lab located here and up and running, and the end of July about how many ticks have you received from Mainers? Dr. Dill. In that short period of time, we received, as of yesterday, 1,837 ticks. The Chairman. So I think that is remarkable because a lot of people are unaware that you will do this service. In fact, I am a little worried that this hearing is going to overwhelm your resources, so that is further reason for me to get the TICK Act passed as soon as I can. Dr. Dill. Exactly. The Chairman. Of those ticks tested so far by the University of Maine, can you give us an idea of approximately what percentage of them carried some sort of disease and Lyme disease specifically? Dr. Dill. Of the ones tested, which was about 1,150 ticks that we have actually tested, 42.5 percent of them have carried some type of pathogen; 37 percent of them actually carried Lyme disease, and of course, that is statewide, and just to carry that further, anaplasmosis was 8 percent and babesiosis was 6 percent. The Chairman. So that is a substantial number. Is the university trying to figure out the geographic distribution and whether there are hot spots in the State? You know, I remember when Lyme disease did not even exist in Maine, and then each year we have seen more and more cases, and also they seem to be expanding northward, but still there seems to be a difference in the geographic distribution. Dr. Dill. Definitely a difference in the geographic distribution. Especially as you go from south to north, it gets fewer and fewer. Coastal areas and southern Maine is really right now our hot spots, but what we are doing is with the surveillance that we are doing with the ticks being tested, we actually have some ongoing work, and we are working with Maine Medical Center, who is doing surveys also in, I think, all 16 counties, and we are testing the ticks for them. So it is a great collaborative effort we have in the State of Maine. So we are looking at this type of thing as we move forward, trying to get some type of distribution. The Chairman. Thank you. Dr. Petersen, in 1947--and, no, I was not alive then. In 1947, we launched the National Malaria Eradication Project, and this Federal program, with State and local participation, succeeded in eradicating malaria from the United States in a very short period of time. I think it was by 1951, and the antimalarial campaign involved large-scale public health initiatives. Our approach to tick disease, tick-borne diseases and Lyme disease, is very fragmented today, and it really relies on the individual, people like Paula and like Chris, with their physicians, to try to figure out what in the world is going on. So with the TICK Act's national strategy, we are seeking to ultimately halt the progression of Lyme disease. That is an ambitious goal. Since you have so much experience with other epidemics and at the CDC, could you explain to us the difference that a larger-scale public health approach at the Federal, State, and local levels could--what promise that holds for Lyme disease control and prevention? Dr. Petersen. Thank you for the question. I think one thing that is very important to know is if we do not do anything large, like on the scale of what you were talking about with malaria, this is just going to continue to get worse and worse, and so there is really an urgent need to try and figure out how to better control these tick-borne diseases in particular. One of the advantages that they had with malaria was that there was DDT and other things that we may not want to use right now that could effectively control the mosquito vectors. Unfortunately, for Lyme disease and other tick-borne diseases, we do not have really good strategies, like a real unified strategy that will work to control these ticks. We really need to find better ways of controlling ticks, and in the meantime, we need to better do better surveillance for the ticks to see where they are, as Dr. Dill has mentioned, as well as trying to figure out how to better diagnose patients, as several of the panel members have mentioned, so there is no simple, easy answer, but it is going to take a concerted effort of State, local, Federal, private institutions all working together to try and find solutions for this growing problem. The Chairman. I was struck in your testimony when you pointed out that there is no vaccine that is available for Lyme disease, and I was thinking about that because my husband and I got a dog a year and a half ago, and we had her vaccinated for Lyme disease. So I know this is not exactly under CDC's purview, but I am sure you are a partner with the NIH and others, but what are the barriers to developing a vaccine? And is that an approach that we should be pursuing? Dr. Petersen. Yes, so we are very in favor of someone producing a very safe and effective vaccine for Lyme disease. I think ultimately this is going to be one of the key answers in trying to control Lyme disease. The key is it has got to be safe and it has got to be effective, and there is just a much higher bar for proving safety and efficacy in humans than there are, let us say, for your dog, with obvious reason, and so there is a company called ``Valneva'' that is in Stage II clinical trials with a Lyme disease vaccine both in the U.S. and in Europe, but it is still going to take several years to be able to bring this vaccine to market. The other thing to keep in mind is a vaccine is not the magic bullet for this. Certainly, if a safe and effective vaccine for Lyme disease is produced, that is great. We have got a huge increase in Lyme disease, but we have to remember that the same tick that spread Lyme disease spreads a lot of other diseases, like anaplasmosis, Powassan, and so it is going to take both an effort of vaccine development as well as better ways of controlling ticks to ultimately find the right solutions for this. The Chairman. I am encouraged to know that there are some Stage II clinical trials going on. That is encouraging. Ms. Jackson Jones, treatment for Lyme disease can be very expensive, and you talked about--I think you said that you went to more than 20 doctors to try to get an accurate diagnosis. We have heard from Chris about his odyssey and having MRIs and CAT scans and even a spinal tap and going to his dentist, who, fortunately, made the link. So talk to me about how expensive it can be to get an accurate diagnosis and treatment. Ms. Jackson Jones. Well, my personal journey, we are in the neighborhood of $250,000, and I stopped counting when I went into remission. There are still support measures and support finances that you go through. There is damage control. You know, my pancreas, my liver, my kidneys were collateral damage in the treatment journey, both from misdiagnosis, you know, all the different antibiotics that I took before finally getting the proper diagnosis. So I could almost double that number easily, because I am still taking support measures today to support my adrenals because I am very active, so just to keep me healthy, but also to piggyback off what Chris said, you know, diet plays a huge part in it, and we all know if you eat healthy, it is not cheap either, so, you know, just trying to stay healthy, stay with a healthy diet, exercise, reduce the stress, there are costs associated with all of that, and it is not something that is affordable by everybody. The Chairman. That is an extraordinary burden on top of the disease. Dr. McCloy, you talked about the disagreements among medical professionals on what should be done, and we also have an issue where the testing produces a lot of false negatives because it takes a while, I assume, for the antibodies to show up, and there is this two-stage blood test. So not to personalize this, but when I had a tick recently, my doctor did not do the test thing. She immediately gave me two doses of doxycycline. Wouldn't it make more sense to start treating even if you have not gotten the test results back yet to prevent long-term damage or to stop the disease in its tracks? Dr. McCloy. That is my own personal approach in my practice as well, but not all physicians would agree with that. I have been surprised at the sort of war going on out there in the medical world, in the medical community, and personal attacks between physicians over this whole Lyme disease question. So I think every physician has differing opinions and a different scale of training and education around what they are doing in their own practices, and the guidelines really do vary on what to do with that kind of circumstance. If you have got a person with a tick bite, do you treat them right away? Do you wait until the results come back? Do you wait until symptoms develop? If it is a pediatric patient, what do you do with a very small child? We have to remember the antibiotics themselves have a lot of side effects and potential damage, too, so it is always a risk/benefit discussion with each individual patient. For me, because I have seen the damage done to chronically ill individuals, I am a little more aggressive in my own strategy, so I definitely would treat early and have the tick sent off for testing and even begin treatment while the tick itself is waiting to come back. The Chairman. Dr. Petersen, are there efforts underway to try to improve the testing process so that you get quicker results or there are not so many false negatives? Dr. Petersen. Absolutely, and I think with the treatment, I think as the Nation's prevention agency, we would say the best treatment for all these diseases is to prevent them in the first place. However, you know, you have had our other panelists as well as people in the audience that have made it quite clear that the burden of the disease is quite high, and I think the first step in treatment is to do the proper diagnosis and get better diagnostic tests, and these are sorely needed, as was mentioned by several of the other panel members, and so we are engaged in a number of efforts to try and improve diagnosis. It is a huge effort on our part. We are working with other Federal agencies such as the NIH, private companies, and academic institutions to try and better improve the diagnosis, not only for Lyme disease but all of the vector-borne diseases. The Chairman. Thank you. Mr. Philbrook--I know you like me to call you ``Mr. Philbrook.'' You know, one of the aspects of your terrible journey with this disease that so impressed me is you just kept trying to figure out what was wrong, and Paula did also. You did not give up, and you have also maintained this unbelievably positive attitude, which is really inspiring. Looking back at your own battle against Lyme disease, what advice would you give to an individual who is newly diagnosed with Lyme or another tick-borne illness? Mr. Philbrook. Sure, and Paula mentioned this in her testimony. I think you need to be your own advocate right from the start. Do not be afraid to bring your physician research that you have seen, things that have worked for other people, because there is often an individualized approach to treating Lyme disease. I also would just say to take it very seriously and give yourself some time to get better. It is attacking your nervous system, so you really need to take that time in your life to get better. The Chairman. Tell me what you do--I know you have a child now, and if you have all been--your family has been outside. Do you check yourself when you come back in? Or what do you do on the prevention side? Mr. Philbrook. Sure. We do a few basic things; like tucking your pants into your socks is an easy way to help prevent ticks from entering your body. The most important thing we have done, honestly, is a very simple step, which is take a shower as soon as we get back inside, whether it is hiking, gardening, just being outside at all, because a lot of times, at least in our experience, the ticks have not attached yet and they wash right off and down the drain, and that has been a huge preventative step we have taken. Obviously, watching much more carefully my daughter than probably most people, but, you know, you check behind the ears, you check in the hair. Vivien Leigh, who is in the audience, did a great service to Mainers and kind of went through a lot of different ways people prevent Lyme disease and different treatment options as well. The Chairman. Thank you. Yes, Dr. McCloy? Dr. McCloy. One thing I try to educate my patients about is that daily tick check, really 365 days a year, and making it part of your daily personal hygiene. So you brush your teeth at night, you do a tick check, and what I tell my patients is you are trying to find a poppy seed on your body, that is how big some of these ticks are. So find the poppy seed, check your partner, make it fun--you know, check your kids. So that is part of your daily routine. The Chairman. Thank you. That is good advice. Ms. Jackson Jones, you talked about the work that you have done. Could you tell us a little bit--I know you put on an annual conference, and explain a little bit about that conference and what its purpose is and what your goals are with your organization on the Midcoast. Ms. Jackson Jones. It is important to us to get resources to people and to introduce them to what all their options are. So every year in the spring we hold an annual Midcoast Lyme Disease Support and Education conference, and we have it slated for April 11th of next year. We had to move it from a small community center to the Augusta Civic Center because we grew so fast. We bring in doctors, researchers, labs, medical facilities, all types of businesses that come in, anybody that has a connection to Lyme and tick-borne disease. We have Dr. Dill come in, and he, you know, shares what the labs are doing. It is important to us to bring what is going on around the world to the people of Maine, and what better way to do it than to bring the speakers in themselves, to bring the researchers in to talk about the latest diagnostics. The labs will share what their latest tests are available. This is good not only for the patients but for the doctors to know what resources are available. So the speakers get a chance to present what is new in the form of diagnostic testing, treatment, support, and then we have anywhere from 100 to 125 exhibitors there where people can go up and actually network for free and get firsthand, one- on-one experience with them, talk to the many different providers. If you are in the market for a new Lyme provider and you just do not know what Dr. McCloy offers or what somebody else offers, talk to them. They have all their information there. You can talk to them, set something up. You can talk to the different labs, find out what testing is going on. You can talk to the different treatment companies that are there and ask, you know, ``What is new? What are you doing to combat Babesia symptoms?''--then talk to other people that are there encouraging exercise and food and stress reduction. More importantly, we do it all for free. It does not cost anything to walk through those doors. We get Federal grants. We get State grants. We get a lot of donations. We do charge our exhibitors to have a booth space there, and we make sure that it is always free. If somebody has got $20 left to their name, I mean, to put that in their tank for gas, just to show up to get connected to resources, we want to make sure that that happens. The Chairman. That makes a great deal of sense, and I know your conference is extremely valuable in educating people. Dr. McCloy, it sounds to me, when we listen to Paula's and Chris' experience, that there is not a one-size-fits-all approach to tick-borne illnesses. Has that been your experience, that you have to tailor it to the individual? Dr. McCloy. Absolutely. Yes, the disease affects different people in different ways, so it depends on which systems of their body it is affecting. That is why it is called ``the great mimicker'' these days. It mimics a lot of other illnesses out there. The diagnosis is quite challenging, too. A lot of physicians go with what is called a ``clinical diagnosis,'' meaning that if this person presents with a good story, if they have been in a Lyme-endemic area, they are outdoors, they get these illnesses, these symptoms present, that you need to rule out the other diseases that can cause those same symptoms, but if they have got 36 out of 38 symptoms of Lyme disease, they probably have Lyme disease, but you still have to do your due diligence as a physician and rule out the lupus and the autoimmune conditions and the fibromyalgia and all these other things that could present similarly, so it takes a lot of time. It is quite challenging to do that as a physician. I think that is one of the limitations in our kind of conventional medical care system, where the physician might have 7 to 11 minutes with a patient per visit. It is hard to figure it out in that amount of time given. The Chairman. I would think that it would be. Dr. Dill, if the TICK Act were to become law, which I am determined that it will, how would it be helpful to you and the important work that you are doing at the university? Dr. Dill. I think one of the things that is happening, of course, there are lots of threats coming in with the ticks. There are new species knocking on our door. There are new diseases associated with them, and even if you just take Lyme disease, there are several different strains of the disease, and some are more virulent than others. Some of the things that would help with us is that I think that even though the stage has been really good to us, as you can see looking at this facility, and in other ways funding still has not kept up with anywhere what it needs to be with education and management strategies, surveillance, and as we were talking as we walked through here, we could probably hire 25 people just in the tick lab in the State of Maine and not make a dent in all the research and that type of thing that needs to be done, so it would just be an awesome, you know, boost to the research side of the community here at the university, the Maine Medical Center, the CDC. We all work together, and it would be a great boost to all of us. The Chairman. Thank you. Dr. Petersen, the TICK Act would also reauthorize the CDC's Regional Centers of Excellence for Vector-borne Diseases at $10 million per year for each of the next 5 years, and I am worried because the funding for those centers expires next year at the end of the fiscal year, so I want to make sure that does not happen, and that is part of the TICK Act as well. Could you share with us how these centers have advanced our understanding of tick-borne diseases and why we should continue to fund them? Dr. Petersen. Yes, thank you for the question. The Centers of Excellence is a new concept that we had following the Zika virus epidemic, and the idea was to try and merge academic institutions with State and local health departments and develop communities of practice in their areas, among multiple States, as well as trying to train the next generation of medical entomologists, like Dr. Dill, which he can testify to the fact that there are very few medical entomologists right now. You mentioned malaria. The CDC, half the staff of CDC used to be in the mid-1940's in entomology. Now when the Zika virus epidemic happened, out of our staff of 12,000 or so, we had 12 medical entomologists, so we need to rebuild this whole field. Some of the examples of the work that the Centers of Excellence have done, one was just to do the tick surveillance, for example. Not only would we want to do more in Maine, but we would want to do more around the whole country, develop a true national tick surveillance network in all the States. Another thing that we are doing here with the Northeast Center of Excellence, for example, is working on this new Asian longhorned tick, trying to figure out what diseases it spreads, where it is, you know, how it infests animals, how it infests people, and so that has been a very important part. We are also working with the various Centers of Excellence on developing better diagnostic tests. As you heard, it was a huge problem with many of the diseases we deal with, so at CDC we have a certain capacity, you know, we have a certain staff, but by incorporating all these Centers of Excellence around the country, it enabled all of our efforts to expand with our university partners, which has been very, very critical and actually has worked well beyond my wildest dreams. The Chairman. That is great to hear. Thank you. Would any of our witnesses like to add anything before we close the hearing? Is there any issue that you want to make sure is on the record that I did not touch on through questions or testimony? Paula. Ms. Jackson Jones. I think the one thing that most patients can agree on is if we miss the window, the early window of opportunity where our infection moves from acute to chronic, that is where things get really muddy. That is where the diagnostic tools start to fail us. That is where the treatment options--there are no instructions. Everything that has ever been written, including in the ICD-10 code for insurance, that has all been written for acute, so one of the biggest hurdles is, you know, once you outgrow that window and you move into Stage II, Stage III, Stage IV, there are no instructions for doctors at that point. They are trying to make you fit into that acute box, and that acute box says you only get 2 weeks of treatment, and they are trying to be creative and think outside the box and think, ``What can we call this so that the insurances will cover it?'' If the doctors cannot even give it a name, how can they treat it? I would like to see--and that is something that I would like to see at a national level. I think we need to give it a name. We need to agree on what we are going to call it. We need to give it an insurance code, and then we need to agree on how we are going to approach it for treatment, but as Senator Dill--excuse me, Dr. Dill----and Dr. Petersen both alluded, I mean, even like with the vaccine, you know, with a treatment plan, it is only going to go after one thing. If you have two or three co-infections, things start to get a little muddy, so I think having treatment options is the answer and stop making it so cookie-cutter. If we have to give it a cookie-cutter name, then we give it an ICD-10 code and we let the doctors go from there and treat their patients. The Chairman. Very good points. Thank you. Dr. Dill? Dr. Dill. I would just add that when we are talking about the statistics on the amount of Lyme disease, et cetera, the one thing I did not mention and it was just brought up was about 8 percent of the ticks tested have had co-infections, so it is prevalent. There is more than one disease associated with an individual tick, and you may be looking at one disease, and you actually have two or three, so it is crucial all the way around. The Chairman. Thank you. Dr. Petersen? Dr. Petersen. Yes, I think one thing that is important is that we absolutely need a very large-scale project or a big effort to try and figure out how to better control these ticks, but in the meantime, I think is very important that people protect themselves against tick bites by wearing permethrin- treated clothing, by putting on insect repellent, by tick- proofing their yard, because you have heard about some of the devastating effects of some of these tick-borne diseases, and the best way to prevent that is to prevent it, and so it is very important that State and local health departments work with academic institutions, private organizations, you know, patient groups to try and spread the world about how people can actually prevent tick bites. I met with the Maine CDC yesterday. They are doing an outstanding job on trying to educate the public on how to do it. It is not so easy. These ticks are very small, but people need to remain vigilant, and we keep--we need to push that effort to make people aware of these kinds of problems and how to prevent them. The Chairman. Thank you. Dr. McCloy? Dr. McCloy. We touched briefly on the financial impact of this disease on patients and individuals and also touched briefly on the insurance companies' coverage of the treatments. As a physician, I often see my patients running up against that barrier where their insurance companies do not approve more than, say, 4 weeks or so of antibiotics, and we have to help them navigate appeals processes, et cetera. Some States have passed legislation mandating the insurance companies to cover for a longer-term treatment, but it has been a little piecemeal, so, again, as part of a national effort, it would be nice to see some sort of legislative effort to mandate insurance companies to cover not only longer-term antibiotics but also the other integrative therapies that Paula has discussed. You know, all these various impacts on her body, you cannot just throw 4 weeks of antibiotics at that kind of a situation. You have to treat it holistically and comprehensively, and that financial limitation is tough for patients, so having insurance coverage mandated would be a huge help for these patients. The Chairman. Well, her $250,000 in medical bills is just such a burden on top of the disease. It is just incredible, and I think the point is well taken that insurers have not figured out that there are chronic cases and with diverse symptoms and that it does not fit neatly into one insurance code for reimbursement, so those are both good points. Chris, we are going to allow you to finish up the testimony today. Mr. Philbrook. Thank you. I hope this act just generates-- and it is generating awareness for people to be thinking about this. Dr. Petersen mentioned prevention, and that is a key piece, but everybody in this room can be an advocate for themselves, can ask their friends that may be going through something like this, if they have asked their doctor about Lyme disease and just consider it as a possibility, and then just keep asking the question. I am excited that this act is on the table because I think it is generating a significant amount of awareness that this disease deserves, so thank you. The Chairman. Thank you. I want to thank all of our witnesses today for sharing your stories, your expertise, and your insights. Your testimony today shines a bright lime-green spotlight on the growing crisis of tick-borne illnesses and is a spur to action. We live in a State where we love being outside. It is part of our heritage in Maine, to be outside, to take that walk in the woods, to go hunting, to do gardening, and we want to be able to continue to enjoy what makes Maine so special, and the great outdoors and the recreational opportunities it offers clearly are part of that, so that is why I have become really determined to look for alternative, broader approaches to attacking this epidemic. Again, I will start where we began, and that is, on a per capita basis, Maine has the highest incidence of Lyme disease in the Nation, so we are particularly affected, and of those Mainers and of people nationwide who get tick-borne illnesses, those aged 65 and older are at particular risk. Since Maine is the oldest State in the Nation by median age, that adds to our vulnerability. Prevention remains so important, as we have just heard from Chris and other witnesses, being an advocate for yourself, but I also believe that we need to turn the corner and adopt a public health approach and make this a national priority just as we did with the eradication of malaria so many years ago, and if we can join forces and collect data and share information, disseminate best practices, raise public awareness, educate health care professionals, work with the researchers in the labs like here at the university, which does such a great job, and work with our partners at the Federal level and with those Regional Centers of Excellence, I believe we can make a real difference. I am grateful for all of our panelists for adding to my knowledge as I continue to advocate in Washington for passage of the TICK Act. I think it truly would help us turn the corner and adopt a whole new public health approach to combating these tick-borne illnesses, so I want to thank all of you for being here today and helping us change the trajectory of tick-borne diseases. I also want to thank my staff, Sara in particular for her very hard work on this issue. She is a public health expert and has helped in developing this new approach that we are going to be pushing hard. My thanks to the University of Maine, the Cooperative Extension Service, and the tick lab in particular for graciously hosting this event. I am very proud of the work that is being done here at the university and hope that with the additional funding that would be available through the TICK Act that we can expand that work and give you even more resources. I have a feeling, after this hearing and with the dissemination of these kits, that that number of ticks that are sent into the lab may well increase, and that is a good thing, but I know you need the staff to handle it as well. The hearing record will remain open until Friday, September 13th, in case there are additional questions that we may be sending your way, but again, my great appreciation to all of you for being here today. You added immensely to our knowledge. My thanks to all of you who have participated in so many ways, so many of you who are sitting in the audience have shared your personal stories with us and your scientific expertise in helping us draft the TICK Act, so I am very grateful for that. This hearing is adjourned. It is official. Thank you. [Whereupon, at 11:26 a.m., the Committee was adjourned.] ======================================================================= APPENDIX ======================================================================= Prepared Witness Statements ======================================================================= [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] ======================================================================= Statements for the Record ======================================================================= [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] [all]